The generics paradox revisited: empirical evidence from regulated markets

Sotiris Vandoros*, Panos Kanavos

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)

Abstract

Earlier studies have pointed at the presence of a generics paradox in the US prescription drug market. This article tests whether the generics paradox also holds in the presence of pricing and reimbursement regulation in six European prescription drug markets. Using proprietary pricing and market share data, the results of panel data analysis suggest that the generics paradox also holds in these markets. Neither generic entry nor generic market penetration affect prices of originator drugs downwards, and prices of originator drugs actually increase post-generic entry.

Original languageEnglish
Article numberN/A
Pages (from-to)3230-3239
Number of pages10
JournalApplied Economics
Volume45
Issue number22
DOIs
Publication statusPublished - 2013

Keywords

  • pharmaceuticals
  • price competition
  • patent expiry
  • generics paradox
  • panel data
  • 1984 DRUG-ACT
  • PRESCRIPTION MEDICINES
  • PATIENT CHARGES
  • PHARMACEUTICALS
  • COMPETITION
  • PRICE
  • IMPACT
  • ENTRY
  • DEMAND

Fingerprint

Dive into the research topics of 'The generics paradox revisited: empirical evidence from regulated markets'. Together they form a unique fingerprint.

Cite this